TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04407351

Intervention type: DEVICE
Group type: OTHER
Intervention: Green LED light
Description: Investigators arrange 12 weeks green LED light phototherapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Green LED light
Description: Investigators arrange 12 weeks green LED light phototherapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: Red LED light (placebo)
Description: Investigators arrange 12 weeks red LED light phototherapy (placebo).

Intervention type: DEVICE
Group type: OTHER
Intervention: Red LED light (placebo)
Description: Investigators arrange 12 weeks red LED light phototherapy (placebo).
Study: NCT04278417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Description: 3 x q6w loading injections, followed by q12w maintenance through Week 90

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal photocoagulation laser
Description: initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed
Study: NCT04499339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLAMF7 CAR-T
Description: Single infusion of autologous SLAMF7 CAR-T cells
Study: NCT01305928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Hand-off
Description: Warm Hand-Off~Staff brief intervention and warm hand-off (5 min):~* Assess withdrawal, need for medication change~* Describe warm hand-off process~* Provide 2-page flyer~* Perform call, leave room~* Notify patients' nurse patient is talking to quitline~Quitline session (20 min):~* Collect minimum data set~* Explore thoughts/feelings toward quitting~* Provide medication education~* Build plan to stay quit~* Schedule next call~Staff check-back (5 min):~* Ask patient how session went~* Ask if patient requests cessation medication script on discharge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fax
Description: Fax~Staff standard in-patient session: (30 minutes):~* Assess withdrawal, need for medication change~* Conduct assessment of smoking history, interest in quitting~* Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting~* Provide 2-page flyer~* Provide medication education~* Build plan to stay quit~* Describe fax-referral process~* Ask if patient requests cessation medication script on discharge
Study: NCT01758874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phlebotomy
Description: repeated phlebotomy for 4 weeks
Study: NCT03236922

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pubococcygeus sling
Description: The pubococcygeus muscles is dissected from the vaginal side walls and approximated at the midline just below the urethra.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus fascia sling
Description: Rectus fascia is dissected out cephalad to the pubic symphysis and tunneled beneath the urethra.
Study: NCT02578511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
Study: NCT00284908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Tenatoprazole-Na (STU-Na)
Description: 30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
Study: NCT01811940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall-ER
Description: MAS-ER 60mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate 100 mg bid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02601586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR Oxycodone
Description: PR Oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Levodopa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone Placebo
Description: Placebo of PR Oxycodone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Placebo
Description: Placebo of PR Oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa placebo
Study: NCT01794117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.
Study: NCT03132623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: andrographolide sulfonate
Description: Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: andrographolide sulfonate simulation
Description: Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
Study: NCT03881033

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peep 5cmH2O
Description: Face mask ventilation with peak inspiratory pressure according to the group P7+5 means face mask ventilation with peak inspiratory pressure 7cmH2O plus PEEP 5 cmH2O.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peak inspiratory pressure
Description: Face mask ventilation with peak inspiratory pressure according to the group P12 means face mask ventilation with peak inspiratory pressure 12cmH2O without PEEP.
Study: NCT00042796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00796536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy
Description: Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain education
Description: Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
Study: NCT03017144

Intervention type: OTHER
Intervention: Pit crew model education
Description: A pit crew model for resuscitation is educated to all resuscitation team members.
Study: NCT02283437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving Based Bibliotherapy Program
Description: The PSBPF will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Management and Education Program
Description: Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the behavioral management and education group, which is guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2001) family management programs for schizophrenia.
Study: NCT04380896

Intervention type: OTHER
Intervention: Blood test
Description: Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.

Intervention type: OTHER
Intervention: Blood test
Description: Blood tests (8ml in total) 4ml blood for serological testing (measure the antibody titres to the SARS-CoV-2 nucleo-capsid protein (4ml) and 4ml EDTA to be stored for future research will be taken for each group.

Intervention type: OTHER
Intervention: Standardised questionnaires
Description: It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.

Intervention type: OTHER
Intervention: Standardised questionnaires
Description: It will be an online questionnaire about staff members health, symptoms of SARS-CoV-2 and contact with SARS-CoV-2. All participants will also be asked to complete a detailed symptom and electronic questionnaire prior to each appointment.
Study: NCT00180713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40mg od for 1 month, then 80mg od for 11 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.
Study: NCT03784352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A calming virtual reality game will be played
Study: NCT00405704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-Sulfamethoxazole
Description: Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cherry flavored liquid suspension matched to active comparator.
Study: NCT03406702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-8998
Description: T-type calcium channel blocker
Study: NCT04520555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Description: LMA Flexible is a supraglottic airway device, which can be moved out of the surgical field without displacement of the cuff, or loss of seal for the anesthetist

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Endotracheal tube is a plain tube, which is most commonly used in general anesthesia.
Study: NCT03467308

Intervention type: GENETIC
Intervention: Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)
Description: The followings markers will be investigated in tissue samples:~1. TIGAR expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~2. TRIM59 expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~P53 expression using immunohistochemistry. P53 nuclear localization is essential for its normal function in growth inhibition or induction of apoptosis.~* Akt expression using western blot.~* GSH using chemical methods.

Intervention type: GENETIC
Intervention: Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)
Description: The followings markers will be investigated in tissue samples:~1. TIGAR expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~2. TRIM59 expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~P53 expression using immunohistochemistry. P53 nuclear localization is essential for its normal function in growth inhibition or induction of apoptosis.~* Akt expression using western blot.~* GSH using chemical methods.
Study: NCT06087562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution 20mL
Description: Ultrasound-guided iPACK block with 20mL of 0,5% ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,9% normal saline 20mL
Description: Ultrasound-guided placebo block with 20mL of 0,9% normal saline
Study: NCT01744925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib of routine dose
Description: Icotinib: 125mg, oral administration, three times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib of high dose
Description: Icotinib: 375mg, oral administration, three times per day.
Study: NCT03027687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS is an electrical brain stimulation method

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS is an electrical brain stimulation method
Study: NCT04660019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scalp and auricular acupuncture
Description: Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of scalp and auricular acupuncture treatment on day 1, 5, 9 and 14.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Seed acupressure
Description: Three scalp acupoints including Baihui (GV 20), bilateral Toulinqi (GB 15, stomach area) and four ear acupoints (Shenmen, thalamus, cardia, stomach). The study duration was 2 weeks with four sessions of seed acupressure treatment on day 1, 5, 9 and 14.
Study: NCT02768558

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: 2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation Therapy (RT)
Description: 2 Gy fractions once a day, 5 days per week, for a total of 60 Gy in 30 fractions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
Study: NCT03396432

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscopy for ET placement
Description: Tracheal intubation performed with the Storz C-Mac Video Laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscopy for ET placement
Description: Tracheal intubation performed with the Storz C-Mac Video Laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy for ET Placement
Description: Tracheal Intubation performed with the Miller Blade

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy for ET Placement
Description: Tracheal Intubation performed with the Miller Blade
Study: NCT00406458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-509
Description: 60 mg dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT03018301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
Study: NCT03222544

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: methylene blue
Description: Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Photon therapy instrument
Description: Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
Study: NCT01719900

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulse fibre
Description: Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control biscuit with no yellow pea hull fibre.
Study: NCT00786890

Intervention type: OTHER
Intervention: observational, no intervention needed
Description: observational, no intervention needed
Study: NCT04453241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP615
Description: Intramuscular injection, 0.5ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: Intramuscular injection, 0.5ml
Study: NCT01639794

Intervention type: DRUG
Intervention: Vesitirim™ (Solifenacin)
Description: Oral
Study: NCT01679613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: low or medium dose depending on pilot part

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: low dose oral administration
Study: NCT04032379

Intervention type: OTHER
Intervention: Standard treatment
Description: No intervention, some patients have additional neuro-psychological testing.

Intervention type: OTHER
Intervention: Standard treatment
Description: No intervention, some patients have additional neuro-psychological testing.

Intervention type: OTHER
Intervention: Standard treatment
Description: No intervention, some patients have additional neuro-psychological testing.
Study: NCT00514046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: once daily continuously (28 day cycles)
Study: NCT03029260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization - tension.
Description: Neural mobilization in tension consists of using combinations of joint movement known to maximize the tension and lengthening of peripheral nervous structures.~The intervention will be delivered in one session only.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural mobilization - gliding
Description: Gliding neural mobilization consists of using combinations of joint movement known to maximize the movement of the peripheral nerves in relation to adjacent structures.~The intervention will be delivered in one session only.
Study: NCT04152850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and Traditional Chinese Medicine
Study: NCT04737213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101
Description: Fluorescence guided surgery
Study: NCT03225846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120102
Description: WVE-120102 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120102
Description: WVE-120102 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120102
Description: WVE-120102 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120102
Description: WVE-120102 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120102
Description: WVE-120102 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride
Study: NCT03695016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActiveGOALs
Description: 13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ActiveGOALs
Description: 13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
Study: NCT03072758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men's Club
Description: Interactive session: This will be a one-day five-hour session that will take place at the church, and will be facilitated by trained lactation nurses. This will involve a maximum of 10 male participants and will occur during the female partner's 3rd trimester. Male partners will (a) complete a structured questionnaire to determine baseline knowledge, attitudes and beliefs about breastfeeding practices, and (b) actively engage in educational information on the benefit of exclusive breastfeeding. At the end of the session, the participants will receive educational pamphlets on breastfeeding to reinforce all the information that had been provided.~Phone call reminders: Participants will receive weekly robocalls during the first six weeks following the birth of the infant to reinforce the benefits of exclusive breastfeeding. This will be an automated service that will deliver the calls at a specific time of the day the participants have indicated on their questionnaire.
Study: NCT02855164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison of different doses of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison of different doses of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison of different doses of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison of different doses of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison of different doses of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Description: Comparison of different doses of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator